<DOC>
	<DOCNO>NCT02369796</DOCNO>
	<brief_summary>The purpose study evaluate effect serum testosterone 4 week subcutaneous ( SC ) dose administration , different dos dose frequency TAK-448 overweight/obese male hypogonadotropic hypogonadism .</brief_summary>
	<brief_title>A Phase 2a Pharmacodynamic Study TAK-448 Participants With Hypogonadotropic Hypogonadism</brief_title>
	<detailed_description>The drug test study call TAK-448 . TAK-448 test treat overweight/obese male hypogonadotropic hypogonadism . This study look effect TAK-448 serum testosterone different dos different dose frequency . The study enroll 15 patient . There 5 cohort participant assign cohort sequential order . Cohorts assign follow treatment group : - TAK-448 3 µg weekly - TAK-448 1 µg weekly - TAK-448 0.3 µg weekly - TAK-448 0.3 µg twice weekly - TAK-448 0.1 µg twice weekly All participant administer study drug via SC injection twice week depend assign cohort four week . This single-center trial conduct United Kingdom . The overall time participate study 32 day . Participants make multiple visit clinic ( depend once-weekly twice-weekly dosing ) , contact telephone 1 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant two morning total serum testosterone ( ST ) concentration ≤12.0 nmol/L ( ≤3.46 ng/mL ) take Screening period . 4 . Is male age 18 60 year , inclusive . 5 . Has body mass index ( BMI ) 25.0 50.0 kg/m^2 , inclusive . 6 . If diagnose type II diabetes mellitus ( T2DM ) , glycosylated hemoglobin ( HbA1c ) concentration &lt; 12 % Screening stable dose 4 diabetes therapy ( include insulin and/or glucagonlike peptide1 therapy ) . 7 . Has luteinizing hormone ( LH ) concentration &lt; 8 IU/L Screening . 8 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 1 . Has receive investigational compound within 30 day prior Screening . 2 . Has receive TAK448 previous clinical study , previous cohort . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , endocrine disease abnormality ( T2DM , complication associate condition ) , may impact ability participant participate potentially confound study result . 5 . Has recent history clinical manifestation significant cardiovascular disease ( CVD ) history myocardial infarction stroke 6 month precede Screening visit untreated peripheral arterial disease . 6 . Has history hypersensitivity allergy component formulation TAK448 . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 5 year prior Screening . 8 . Is required take exclude medication , supplement , food product . 9 . Intends donate sperm course study 12 week last dose study drug . 10 . Has clinical evidence anatomic pathological hypothalamic/pituitary disease . 11 . Is find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take TAK448 , similar drug class might interfere conduct study . 12 . Has history cancer ( include prostate cancer ) , exception basal cell carcinoma remission least 5 year prior Screening . 13 . Has history present prostate disease ( include benign prostatic hyperplasia ) prostatespecific antigen ( PSA ) &gt; 4 ng/mL Screening . 14 . Has know history human immunodeficiency virus infection Screening . 15 . Is deem study team poor peripheral venous access . 16 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 45 day prior Screening , plan donate blood 12 week last dose study medication . 17 . Has Screening Day 1 abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator medically qualify subinvestigator . 18 . Has abnormal Screening Day 1 laboratory value suggest clinically significant underlying disease participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2× upper limit normal ( ULN ) . 19 . The participant , opinion investigator , unlikely comply protocol unsuitable reason . 20 . Has two severe hypoglycemic event ( require third party assistance ) within 6 month prior Screening Visit . 21 . Has diagnosis type 1 diabetes mellitus . 22 . Has history diabetic ketoacidosis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>